Products for Research Use Only
RegisterLogin

Utreloxastat

CAT: 0804-HY-132845-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-132845-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Utreloxastat (PTC857) is an orally active and blood-brain barrier-permeable 15-lipooxygenase inhibitor. Utreloxastat is a weak inhibitor of CYP1A2 and 2B6 with an IC50 of >5.3 μM. Utreloxastat reduces oxidative stress and inhibits the consumption of reduced glutathione and ferroptosis. Utreloxastat can be used in the study of neurodegenerative diseases characterized by high levels of oxidative stress and mitochondrial pathology, such as amyotrophic lateral sclerosisc[1][2].
CAS Number
1213269-96-5
Product Name Alternative
PTC857
UNSPSC
12352211
Target
Cytochrome P450; Ferroptosis; Lipoxygenase; α-synuclein
Type
Reference compound
Related Pathways
Apoptosis; Metabolic Enzyme/Protease; Neuronal Signaling
Applications
Neuroscience-Neurodegeneration
Field of Research
Neurological Disease
Assay Protocol
https://www.medchemexpress.com/utreloxastat.html
Purity
99.69
Solubility
DMSO : 50 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O=C1C(C)=C(C)C(C(C)=C1CCCCCCCCC)=O
Molecular Formula
C18H28O2
Molecular Weight
276.41
References & Citations
[1]Andrew W. Hinman, et al. 2,3,5-TRIMETHYL-6-NONYLCYCLOHEXA-2,5-DIENE-1,4-DIONE FOR SUPPRESSING AND TREATING α-SYNUCLEINOPATHIES, TAUOPATHIES, AND OTHER DISORDERS. WO2020081879A2.|[2]Gao L, et al. First-in-Human Studies of Pharmacokinetics and Safety of Utreloxastat (PTC857), a Novel 15-Lipooxygenase Inhibitor for the Treatment of Amyotrophic Lateral Sclerosis. Clin Pharmacol Drug Dev. 2023 Feb;12 (2) :141-151.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
CYP1A2

Alternative Products

CatalogName
BA8585-5.1Utreloxastat

Popular Products